Corcept Therapeutics (CORT) Upgraded by ValuEngine to “Hold”
ValuEngine upgraded shares of Corcept Therapeutics (NASDAQ:CORT) from a sell rating to a hold rating in a research note published on Thursday morning.
CORT has been the topic of a number of other research reports. B. Riley lowered their target price on shares of Corcept Therapeutics from $30.00 to $22.00 and set a buy rating on the stock in a research note on Monday, August 13th. BidaskClub raised shares of Corcept Therapeutics from a hold rating to a buy rating in a research note on Saturday, May 19th. Cantor Fitzgerald initiated coverage on shares of Corcept Therapeutics in a research note on Thursday, August 23rd. They issued a neutral rating and a $17.00 target price on the stock. Finally, Stifel Nicolaus cut shares of Corcept Therapeutics from a buy rating to a hold rating and set a $20.00 target price on the stock. in a research note on Thursday, May 31st. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $21.83.
NASDAQ:CORT opened at $15.00 on Thursday. Corcept Therapeutics has a 52-week low of $11.55 and a 52-week high of $25.96. The stock has a market cap of $1.60 billion, a PE ratio of 34.09 and a beta of 1.70.
In other Corcept Therapeutics news, insider Robert S. Fishman sold 8,000 shares of the business’s stock in a transaction dated Friday, July 6th. The shares were sold at an average price of $15.09, for a total value of $120,720.00. Following the transaction, the insider now directly owns 8,000 shares in the company, valued at $120,720. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director G Leonard Baker, Jr. purchased 35,681 shares of Corcept Therapeutics stock in a transaction on Monday, August 20th. The stock was purchased at an average price of $12.92 per share, for a total transaction of $460,998.52. Following the completion of the transaction, the director now owns 876,838 shares of the company’s stock, valued at $11,328,746.96. The disclosure for this purchase can be found here. In the last three months, insiders purchased 321,159 shares of company stock worth $4,025,880 and sold 24,000 shares worth $379,760. Insiders own 15.00% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in CORT. Tyers Asset Management LLC acquired a new position in Corcept Therapeutics in the first quarter valued at about $136,000. Asset Management One Co. Ltd. acquired a new position in Corcept Therapeutics in the first quarter valued at about $150,000. Riverhead Capital Management LLC acquired a new position in Corcept Therapeutics in the first quarter valued at about $155,000. Flinton Capital Management LLC acquired a new position in Corcept Therapeutics in the first quarter valued at about $173,000. Finally, Stifel Financial Corp acquired a new position in Corcept Therapeutics in the first quarter valued at about $182,000. Hedge funds and other institutional investors own 74.79% of the company’s stock.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.
See Also: How to Invest in Growth Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.